{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T11:21:11Z","timestamp":1792495271143,"version":"4.5.0"},"reference-count":140,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100010012","name":"National Aerospace Science Foundation of China","doi-asserted-by":"publisher","award":["81603339"],"award-info":[{"award-number":["81603339"]}],"id":[{"id":"10.13039\/501100010012","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010012","name":"National Aerospace Science Foundation of China","doi-asserted-by":"publisher","award":["81602344"],"award-info":[{"award-number":["81602344"]}],"id":[{"id":"10.13039\/501100010012","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003995","name":"Natural Science Foundation of Anhui Province","doi-asserted-by":"publisher","award":["1708085QH175"],"award-info":[{"award-number":["1708085QH175"]}],"id":[{"id":"10.13039\/501100003995","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["18CDA34110359"],"award-info":[{"award-number":["18CDA34110359"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["WK9110000079"],"award-info":[{"award-number":["WK9110000079"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Lipid Research"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.plipres.2019.101006","type":"journal-article","created":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T19:06:58Z","timestamp":1567796818000},"page":"101006","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":236,"special_numbering":"C","title":["ATP-citrate lyase (ACLY) in lipid metabolism and atherosclerosis: An updated review"],"prefix":"10.1016","volume":"77","author":[{"given":"Xiaojun","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suowen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai-zong","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.plipres.2019.101006_bb0005","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1210\/er.2018-00184","article-title":"The forgotten lipids: triglycerides, remnant cholesterol, and atherosclerotic cardiovascular disease risk","volume":"40","author":"Sandesara","year":"2019","journal-title":"Endocr Rev"},{"issue":"8","key":"10.1016\/j.plipres.2019.101006_bb0010","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.tips.2018.06.001","article-title":"Novel therapeutic targets for managing dyslipidemia","volume":"39","author":"Sathiyakumar","year":"2018","journal-title":"Trends Pharmacol Sci"},{"issue":"4","key":"10.1016\/j.plipres.2019.101006_bb0015","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.tips.2019.02.004","article-title":"Targeting mechanosensitive transcription factors in atherosclerosis","volume":"40","author":"Niu","year":"2019","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.plipres.2019.101006_bb0020","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.pharmthera.2018.11.003","article-title":"Targeting epigenetics and non-coding RNAs in atherosclerosis: from mechanisms to therapeutics","volume":"196","author":"Xu","year":"2019","journal-title":"Pharmacol Ther"},{"issue":"32","key":"10.1016\/j.plipres.2019.101006_bb0025","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur Heart J"},{"issue":"11","key":"10.1016\/j.plipres.2019.101006_bb0030","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s11886-015-0659-8","article-title":"Lipid-lowering drug therapy for CVD prevention: looking into the future","volume":"17","author":"Stein","year":"2015","journal-title":"Curr Cardiol Rep"},{"issue":"25 Pt B","key":"10.1016\/j.plipres.2019.101006_bb0035","article-title":"ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"63","author":"Stone","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.plipres.2019.101006_bb0040","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1161\/ATVBAHA.115.306442","article-title":"Nonstatin low-density lipoprotein-lowering therapy and cardiovascular risk reduction-statement from ATVB council","volume":"35","author":"Hegele","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"31","key":"10.1016\/j.plipres.2019.101006_bb0045","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1093\/eurheartj\/ehv182","article-title":"The 2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk: a new paradigm supported by more evidence","volume":"36","author":"Robinson","year":"2015","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.plipres.2019.101006_bb0050","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1097\/MJT.0000000000000063","article-title":"New and emerging LDL cholesterol-lowering drugs","volume":"22","author":"Kosmas","year":"2015","journal-title":"Am J Ther"},{"issue":"24","key":"10.1016\/j.plipres.2019.101006_bb0055","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1093\/eurheartj\/eht088","article-title":"New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs","volume":"34","author":"Norata","year":"2013","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.plipres.2019.101006_bb0060","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1161\/CIRCRESAHA.118.313171","article-title":"Lipid-lowering agents","volume":"124","author":"Hegele","year":"2019","journal-title":"Circ Res"},{"issue":"12","key":"10.1016\/j.plipres.2019.101006_bb0065","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1080\/14656566.2017.1340941","article-title":"Lomitapide for the treatment of hypercholesterolemia","volume":"18","author":"Berberich","year":"2017","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.plipres.2019.101006_bb0070","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.atherosclerosissup.2015.02.005","article-title":"Mipomersen and lomitapide: two new drugs for the treatment of homozygous familial hypercholesterolemia","volume":"18","author":"Gouni-Berthold","year":"2015","journal-title":"Atheroscler Suppl"},{"issue":"5","key":"10.1016\/j.plipres.2019.101006_bb0075","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s11883-016-0579-0","article-title":"Recent developments in gene therapy for homozygous familial hypercholesterolemia","volume":"18","author":"Ajufo","year":"2016","journal-title":"Curr Atheroscler Rep"},{"issue":"5","key":"10.1016\/j.plipres.2019.101006_bb0080","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1210\/jc.2011-3002","article-title":"Effect of alipogene tiparvovec (AAV1-LPL(S447X)) on postprandial chylomicron metabolism in lipoprotein lipase-deficient patients","volume":"97","author":"Carpentier","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.plipres.2019.101006_bb0085","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1056\/NEJMoa1501365","article-title":"A phase 3 trial of sebelipase alfa in lysosomal acid lipase deficiency","volume":"373","author":"Burton","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.plipres.2019.101006_bb0090","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1161\/CIRCRESAHA.115.306223","article-title":"Safety and tolerability of ACP-501, a recombinant human lecithin:cholesterol Acyltransferase, in a phase 1 single-dose escalation study","volume":"118","author":"Shamburek","year":"2016","journal-title":"Circ Res"},{"issue":"15","key":"10.1016\/j.plipres.2019.101006_bb0095","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1615758","article-title":"Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol","volume":"376","author":"Ray","year":"2017","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.plipres.2019.101006_bb0100","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1056\/NEJMoa1806747","article-title":"Mendelian randomization study of ACLY and cardiovascular disease","volume":"380","author":"Ference","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.plipres.2019.101006_bb0105","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/MOL.0000000000000390","article-title":"ATP-citrate lyase: genetics, molecular biology and therapeutic target for dyslipidemia","volume":"28","author":"Burke","year":"2017","journal-title":"Curr Opin Lipidol"},{"issue":"18","key":"10.1016\/j.plipres.2019.101006_bb0110","doi-asserted-by":"crossref","first-page":"7259","DOI":"10.1074\/jbc.RA118.006685","article-title":"ATP-citrate lyase multimerization is required for coenzyme-A substrate binding and catalysis","volume":"294","author":"Bazilevsky","year":"2019","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.plipres.2019.101006_bb0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MOL.0000000000000565","article-title":"Bempedoic acid: effects on lipoprotein metabolism and atherosclerosis","volume":"30","author":"Burke","year":"2019","journal-title":"Curr Opin Lipidol"},{"issue":"7753","key":"10.1016\/j.plipres.2019.101006_bb0120","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/s41586-019-1095-5","article-title":"Structure of ATP citrate lyase and the origin of citrate synthase in the Krebs cycle","volume":"568","author":"Verschueren","year":"2019","journal-title":"Nature"},{"issue":"5930","key":"10.1016\/j.plipres.2019.101006_bb0125","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1126\/science.1164097","article-title":"ATP-citrate lyase links cellular metabolism to histone acetylation","volume":"324","author":"Wellen","year":"2009","journal-title":"Science (New York, NY)"},{"issue":"2","key":"10.1016\/j.plipres.2019.101006_bb0130","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.molcel.2017.06.008","article-title":"Nuclear acetyl-CoA production by ACLY promotes homologous recombination","volume":"67","author":"Sivanand","year":"2017","journal-title":"Mol Cell"},{"issue":"7753","key":"10.1016\/j.plipres.2019.101006_bb0135","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/s41586-019-1094-6","article-title":"An allosteric mechanism for potent inhibition of human ATP-citrate lyase","volume":"568","author":"Wei","year":"2019","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.plipres.2019.101006_bb0140","doi-asserted-by":"crossref","first-page":"9557","DOI":"10.1074\/jbc.M310512200","article-title":"ATP-citrate lyase deficiency in the mouse","volume":"279","author":"Beigneux","year":"2004","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1016\/j.plipres.2019.101006_bb0145","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1016\/S0021-9258(19)40033-1","article-title":"Rat ATP citrate-lyase. Molecular cloning and sequence analysis of a full-length cDNA and mRNA abundance as a function of diet, organ, and age","volume":"265","author":"Elshourbagy","year":"1990","journal-title":"J Biol Chem"},{"issue":"42","key":"10.1016\/j.plipres.2019.101006_bb0150","doi-asserted-by":"crossref","first-page":"32606","DOI":"10.1074\/jbc.M110.157172","article-title":"ATP-citrate lyase reduction mediates palmitate-induced apoptosis in pancreatic beta cells","volume":"285","author":"Chu","year":"2010","journal-title":"J Biol Chem"},{"issue":"17","key":"10.1016\/j.plipres.2019.101006_bb0155","doi-asserted-by":"crossref","first-page":"12497","DOI":"10.1074\/jbc.275.17.12497","article-title":"Transcriptional regulation of the ATP citrate-lyase gene by sterol regulatory element-binding proteins","volume":"275","author":"Sato","year":"2000","journal-title":"J Biol Chem"},{"issue":"20","key":"10.1016\/j.plipres.2019.101006_bb0160","doi-asserted-by":"crossref","first-page":"8547","DOI":"10.1158\/0008-5472.CAN-08-1235","article-title":"ATP citrate lyase: activation and therapeutic implications in non-small cell lung cancer","volume":"68","author":"Migita","year":"2008","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.plipres.2019.101006_bb0165","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1021\/bi992159y","volume":"39","author":"Potapova","year":"2000","journal-title":"Biochemistry"},{"issue":"37","key":"10.1016\/j.plipres.2019.101006_bb0170","doi-asserted-by":"crossref","first-page":"21758","DOI":"10.1074\/jbc.270.37.21758","article-title":"Phosphorylation of ATP-citrate lyase by nucleoside diphosphate kinase","volume":"270","author":"Wagner","year":"1995","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.plipres.2019.101006_bb0175","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.cmet.2014.06.004","article-title":"Akt-dependent metabolic reprogramming regulates tumor cell histone acetylation","volume":"20","author":"Lee","year":"2014","journal-title":"Cell Metab"},{"key":"10.1016\/j.plipres.2019.101006_bb0180","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.11612","article-title":"Akt-mTORC1 signaling regulates Acly to integrate metabolic input to control of macrophage activation","volume":"5","author":"Covarrubias","year":"2016","journal-title":"eLife"},{"issue":"6","key":"10.1016\/j.plipres.2019.101006_bb0185","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1074\/mcp.M115.057158","article-title":"Nuclear Phosphoproteomic screen uncovers ACLY as mediator of IL-2-induced proliferation of CD4+ T lymphocytes","volume":"15","author":"Osinalde","year":"2016","journal-title":"Mol Cell Proteomics"},{"issue":"12","key":"10.1016\/j.plipres.2019.101006_bb0190","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1038\/labinvest.2015.115","article-title":"The expression of genes involved in jejunal lipogenesis and lipoprotein synthesis is altered in morbidly obese subjects with insulin resistance","volume":"95","author":"Gutierrez-Repiso","year":"2015","journal-title":"Lab Invest"},{"issue":"2","key":"10.1016\/j.plipres.2019.101006_bb0195","first-page":"1955","article-title":"Weighted gene coexpression network analysis in identification of key genes and networks for ischemicreperfusion remodeling myocardium","volume":"18","author":"Guo","year":"2018","journal-title":"Mol Med Rep"},{"issue":"2","key":"10.1016\/j.plipres.2019.101006_bb0200","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.yexcr.2019.04.006","article-title":"KDM5B promotes breast cancer cell proliferation and migration via AMPK-mediated lipid metabolism reprogramming","volume":"379","author":"Zhang","year":"2019","journal-title":"Exp Cell Res"},{"issue":"28","key":"10.1016\/j.plipres.2019.101006_bb0205","doi-asserted-by":"crossref","first-page":"44252","DOI":"10.18632\/oncotarget.10020","article-title":"miR\u221222 inhibits tumor growth and metastasis by targeting ATP citrate lyase: evidence in osteosarcoma, prostate cancer, cervical cancer and lung cancer","volume":"7","author":"Xin","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.plipres.2019.101006_bb0210","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.gene.2018.05.072","article-title":"Obesity-induced overexpression of miRNA-24 regulates cholesterol uptake and lipid metabolism by targeting SR-B1","volume":"668","author":"Wang","year":"2018","journal-title":"Gene"},{"issue":"17","key":"10.1016\/j.plipres.2019.101006_bb0215","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1101\/gad.283283.116","article-title":"Cullin3-KLHL25 ubiquitin ligase targets ACLY for degradation to inhibit lipid synthesis and tumor progression","volume":"30","author":"Zhang","year":"2016","journal-title":"Genes Dev"},{"key":"10.1016\/j.plipres.2019.101006_bb0220","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12957-015-0440-x","article-title":"Functional polymorphisms of ATP citrate lyase gene predicts clinical outcome of patients with advanced colorectal cancer","volume":"13","author":"Xie","year":"2015","journal-title":"World J Surg Oncol"},{"issue":"17","key":"10.1016\/j.plipres.2019.101006_bb0225","first-page":"7097","article-title":"Fatty acid synthesis pathway genetic variants and clinical outcome of non-small cell lung cancer patients after surgery","volume":"15","author":"Jin","year":"2014","journal-title":"APJCP"},{"issue":"3","key":"10.1016\/j.plipres.2019.101006_bb0230","first-page":"1051","article-title":"Polymorphisms in genes of the de novo lipogenesis pathway and overall survival of hepatocellular carcinoma patients undergoing transarterial chemoembolization","volume":"16","author":"Wu","year":"2015","journal-title":"APJCP"},{"issue":"10","key":"10.1016\/j.plipres.2019.101006_bb0235","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1194\/jlr.M041590","article-title":"Polymorphisms, de novo lipogenesis, and plasma triglyceride response following fish oil supplementation","volume":"54","author":"Bouchard-Mercier","year":"2013","journal-title":"J Lipid Res"},{"issue":"8","key":"10.1016\/j.plipres.2019.101006_bb0240","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1007\/s10072-014-1671-2","article-title":"Genome-wide pathway analysis in attention-deficit\/hyperactivity disorder","volume":"35","author":"Lee","year":"2014","journal-title":"Neurol Sci"},{"issue":"3","key":"10.1016\/j.plipres.2019.101006_bb0245","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.jacl.2015.01.002","article-title":"Adenosine triphosphate citrate lyase: emerging target in the treatment of dyslipidemia","volume":"9","author":"Lemus","year":"2015","journal-title":"J Clin Lipidol"},{"issue":"4","key":"10.1016\/j.plipres.2019.101006_bb0250","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ccr.2005.09.008","article-title":"ATP citrate lyase inhibition can suppress tumor cell growth","volume":"8","author":"Hatzivassiliou","year":"2005","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.plipres.2019.101006_bb0255","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.bbrc.2013.09.037","article-title":"ATP-citrate lyase is essential for macrophage inflammatory response","volume":"440","author":"Infantino","year":"2013","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.plipres.2019.101006_bb0260","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.3389\/fimmu.2018.02858","article-title":"Polarization of human macrophages by interleukin-4 does not require ATP-citrate lyase","volume":"9","author":"Namgaladze","year":"2018","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.plipres.2019.101006_bb0265","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.celrep.2016.09.069","article-title":"ATP-citrate lyase controls a glucose-to-acetate metabolic switch","volume":"17","author":"Zhao","year":"2016","journal-title":"Cell Rep"},{"issue":"4","key":"10.1016\/j.plipres.2019.101006_bb0270","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1002\/hep.22774","article-title":"Abrogation of hepatic ATP-citrate lyase protects against fatty liver and ameliorates hyperglycemia in leptin receptor-deficient mice","volume":"49","author":"Wang","year":"2009","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.plipres.2019.101006_bb0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2019.04.112","article-title":"Adipocyte ACLY facilitates dietary carbohydrate handling to maintain metabolic homeostasis in females","volume":"27","author":"Fernandez","year":"2019","journal-title":"Cell Rep"},{"issue":"7","key":"10.1016\/j.plipres.2019.101006_bb0280","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1161\/ATVBAHA.118.311212","article-title":"Metformin and AMP kinase activation increase expression of the sterol transporters ABCG5\/8 (ATP-binding cassette transporter G5\/G8) with potential antiatherogenic consequences","volume":"38","author":"Molusky","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"5","key":"10.1016\/j.plipres.2019.101006_bb0285","doi-asserted-by":"crossref","first-page":"930","DOI":"10.4161\/auto.28235","article-title":"Dimethyl alpha-ketoglutarate inhibits maladaptive autophagy in pressure overload-induced cardiomyopathy","volume":"10","author":"Marino","year":"2014","journal-title":"Autophagy"},{"issue":"10","key":"10.1016\/j.plipres.2019.101006_bb0290","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0109663","article-title":"Hepatic carboxylesterase 1 is induced by glucose and regulates postprandial glucose levels","volume":"9","author":"Xu","year":"2014","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.plipres.2019.101006_bb0295","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.atherosclerosis.2014.10.099","article-title":"ETC-1002: a future option for lipid disorders?","volume":"237","author":"Nikolic","year":"2014","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.plipres.2019.101006_bb0300","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/CRD.0000000000000218","article-title":"Bempedoic acid (ETC-1002): ATP citrate Lyase inhibitor: review of a first-in-class medication with potential benefit in statin-refractory cases","volume":"27","author":"Zagelbaum","year":"2019","journal-title":"Cardiol Rev"},{"issue":"1","key":"10.1016\/j.plipres.2019.101006_bb0305","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1194\/jlr.M030528","article-title":"AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism","volume":"54","author":"Pinkosky","year":"2013","journal-title":"J Lipid Res"},{"issue":"1","key":"10.1016\/j.plipres.2019.101006_bb0310","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1021\/jm050650j","article-title":"Influence of various central moieties on the hypolipidemic properties of long hydrocarbon chain diols and diacids","volume":"49","author":"Oniciu","year":"2006","journal-title":"J Med Chem"},{"issue":"7","key":"10.1016\/j.plipres.2019.101006_bb0315","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1194\/jlr.M400018-JLR200","article-title":"Effects of a novel dual lipid synthesis inhibitor and its potential utility in treating dyslipidemia and metabolic syndrome","volume":"45","author":"Cramer","year":"2004","journal-title":"J Lipid Res"},{"key":"10.1016\/j.plipres.2019.101006_bb0320","doi-asserted-by":"crossref","first-page":"13457","DOI":"10.1038\/ncomms13457","article-title":"Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis","volume":"7","author":"Pinkosky","year":"2016","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.plipres.2019.101006_bb0325","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1161\/ATVBAHA.117.310676","article-title":"Bempedoic acid lowers low-density lipoprotein cholesterol and attenuates atherosclerosis in low-density lipoprotein receptor-deficient (LDLR(+\/\u2212) and LDLR(\u2212\/\u2212)) Yucatan miniature pigs","volume":"38","author":"Burke","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"12","key":"10.1016\/j.plipres.2019.101006_bb0330","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1042\/BCJ20180714","article-title":"AMP-activated protein kinase complexes containing the beta2 regulatory subunit are up-regulated during and contribute to adipogenesis","volume":"476","author":"Katwan","year":"2019","journal-title":"Biochem J"},{"issue":"18","key":"10.1016\/j.plipres.2019.101006_bb0335","first-page":"1780","article-title":"Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the clear wisdom randomized clinical trial.","volume":"322","author":"JAMA","year":"2019"},{"issue":"2","key":"10.1016\/j.plipres.2019.101006_bb0340","doi-asserted-by":"crossref","first-page":"207","DOI":"10.5603\/KP.a2019.0013","article-title":"Safety and efficacy of ETC-1002 in hypercholesterolaemic patients: a meta-analysis of randomised controlled trials","volume":"77","author":"Wang","year":"2019","journal-title":"Kardiol Pol"},{"issue":"4","key":"10.1016\/j.plipres.2019.101006_bb0345","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1161\/ATVBAHA.116.308963","article-title":"Prevention of diet-induced metabolic dysregulation, inflammation, and atherosclerosis in Ldlr(\u2212\/\u2212) mice by treatment with the ATP-citrate Lyase inhibitor bempedoic acid","volume":"37","author":"Samsoondar","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"13","key":"10.1016\/j.plipres.2019.101006_bb0350","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.jacc.2013.05.050","volume":"62","author":"Ballantyne","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.plipres.2019.101006_bb0355","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1161\/ATVBAHA.113.302677","article-title":"Efficacy and safety of ETC-1002, a novel investigational low-density lipoprotein-cholesterol-lowering therapy for the treatment of patients with hypercholesterolemia and type 2 diabetes mellitus","volume":"34","author":"Gutierrez","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"12","key":"10.1016\/j.plipres.2019.101006_bb0360","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1016\/j.amjcard.2016.03.043","article-title":"Effect of ETC-1002 on serum low-density lipoprotein cholesterol in hypercholesterolemic patients receiving statin therapy","volume":"117","author":"Ballantyne","year":"2016","journal-title":"Am J Cardiol"},{"issue":"11","key":"10.1016\/j.plipres.2019.101006_bb0365","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1056\/NEJMoa1803917","article-title":"Safety and efficacy of Bempedoic acid to reduce LDL cholesterol","volume":"380","author":"Ray","year":"2019","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.plipres.2019.101006_bb0370","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.jacl.2015.03.003","article-title":"Use of ETC-1002 to treat hypercholesterolemia in patients with statin intolerance","volume":"9","author":"Thompson","year":"2015","journal-title":"J Clin Lipidol"},{"issue":"3","key":"10.1016\/j.plipres.2019.101006_bb0375","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.jacl.2015.12.025","article-title":"Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance","volume":"10","author":"Thompson","year":"2016","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.plipres.2019.101006_bb0380","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.atherosclerosis.2018.06.002","article-title":"Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized, placebo-controlled study","volume":"277","author":"Ballantyne","year":"2018","journal-title":"Atherosclerosis"},{"issue":"7","key":"10.1016\/j.plipres.2019.101006_bb0385","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.011662","article-title":"Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance","volume":"8","author":"Laufs","year":"2019","journal-title":"J Am Heart Assoc"},{"issue":"4","key":"10.1016\/j.plipres.2019.101006_bb0390","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.jacl.2019.05.003","article-title":"Complementary low-density lipoprotein-cholesterol lowering and pharmacokinetics of adding bempedoic acid (ETC-1002) to high-dose atorvastatin background therapy in hypercholesterolemic patients: a randomized placebo-controlled trial","volume":"13","author":"Lalwani","year":"2019","journal-title":"J Clin Lipidol"},{"issue":"4","key":"10.1016\/j.plipres.2019.101006_bb0395","first-page":"396","article-title":"Apolipoprotein E*3-Leiden transgenic mice as a test model for hypolipidaemic drugs","volume":"48","author":"van Vlijmen","year":"1998","journal-title":"Arzneimittel-Forschung"},{"issue":"Pt 1","key":"10.1016\/j.plipres.2019.101006_bb0400","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1042\/bj3340113","article-title":"The role of ATP citrate-lyase in the metabolic regulation of plasma lipids. Hypolipidaemic effects of SB-204990, a lactone prodrug of the potent ATP citrate-lyase inhibitor SB-201076","volume":"334","author":"Pearce","year":"1998","journal-title":"Biochem J"},{"issue":"1","key":"10.1016\/j.plipres.2019.101006_bb0405","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.metabol.2003.07.012","article-title":"The role of adenosine triphosphate citrate lyase in the metabolism of acetyl coenzyme a and function of blood platelets in diabetes mellitus","volume":"53","author":"Michno","year":"2004","journal-title":"Metab Clin Exp"},{"issue":"3","key":"10.1016\/j.plipres.2019.101006_bb0410","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1017\/S0007114517000137","article-title":"Fetal and neonatal exposure to trans-fatty acids impacts on susceptibility to atherosclerosis in apo E*3 Leiden mice","volume":"117","author":"Gates","year":"2017","journal-title":"Br J Nutr"},{"issue":"6","key":"10.1016\/j.plipres.2019.101006_bb0415","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S0022-2275(20)32542-6","article-title":"Effects of dietary fish oil on serum lipids and VLDL kinetics in hyperlipidemic apolipoprotein E*3-Leiden transgenic mice","volume":"39","author":"van Vlijmen","year":"1998","journal-title":"J Lipid Res"},{"issue":"1","key":"10.1016\/j.plipres.2019.101006_bb0420","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jacc.2018.04.040","article-title":"The role of nutraceuticals in statin intolerant patients","volume":"72","author":"Banach","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl. 1","key":"10.1016\/j.plipres.2019.101006_bb0425","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.21037\/cdt.2017.03.20","article-title":"The role of nutraceuticals in the prevention of cardiovascular disease","volume":"7","author":"Sosnowska","year":"2017","journal-title":"Cardiovascular Diagn Ther"},{"issue":"9","key":"10.1016\/j.plipres.2019.101006_bb0430","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1093\/nutrit\/nux047","article-title":"Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel","volume":"75","author":"Cicero","year":"2017","journal-title":"Nutr Rev"},{"issue":"5","key":"10.1016\/j.plipres.2019.101006_bb0435","doi-asserted-by":"crossref","first-page":"965","DOI":"10.5114\/aoms.2017.69326","article-title":"Lipid lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel","volume":"13","author":"Cicero","year":"2017","journal-title":"Arch Med Sci"},{"key":"10.1016\/j.plipres.2019.101006_bb0440","article-title":"Curcumin, the golden spice in treating cardiovascular diseases","author":"Li","year":"2019","journal-title":"Biotechnol Adv"},{"issue":"7","key":"10.1016\/j.plipres.2019.101006_bb0445","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.7150\/thno.30787","article-title":"Berberine in cardiovascular and metabolic diseases: from mechanisms to therapeutics","volume":"9","author":"Feng","year":"2019","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.plipres.2019.101006_bb0450","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/med.21438","article-title":"Atheroprotective effects and molecular targets of tanshinones derived from herbal medicine danshen","volume":"38","author":"Fang","year":"2018","journal-title":"Med Res Rev"},{"issue":"1","key":"10.1016\/j.plipres.2019.101006_bb0455","doi-asserted-by":"crossref","first-page":"422","DOI":"10.3382\/ps\/pey315","article-title":"Curcumin supplementation regulates lipid metabolism in broiler chickens","volume":"98","author":"Xie","year":"2019","journal-title":"Poult Sci"},{"issue":"12","key":"10.1016\/j.plipres.2019.101006_bb0460","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1080\/13880209.2016.1187179","article-title":"Curcumin inhibits hyperlipidemia and hepatic fat accumulation in high-fructose-fed male Wistar rats","volume":"54","author":"Maithilikarpagaselvi","year":"2016","journal-title":"Pharm Biol"},{"issue":"1","key":"10.1016\/j.plipres.2019.101006_bb0465","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s12937-017-0293-y","article-title":"Efficacy and safety of turmeric and curcumin in lowering blood lipid levels in patients with cardiovascular risk factors: a meta-analysis of randomized controlled trials","volume":"16","author":"Qin","year":"2017","journal-title":"Nutr J"},{"issue":"4b","key":"10.1016\/j.plipres.2019.101006_bb0470","first-page":"2895","article-title":"Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions","volume":"21","author":"Cheng","year":"2001","journal-title":"Anticancer Res"},{"issue":"6","key":"10.1016\/j.plipres.2019.101006_bb0475","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1021\/mp700113r","article-title":"Bioavailability of curcumin: problems and promises","volume":"4","author":"Anand","year":"2007","journal-title":"Mol Pharm"},{"issue":"3","key":"10.1016\/j.plipres.2019.101006_bb0480","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3109\/10837451003774377","article-title":"Aqueous solubility of crystalline and amorphous drugs: challenges in measurement","volume":"16","author":"Murdande","year":"2011","journal-title":"Pharm Dev Technol"},{"issue":"1","key":"10.1016\/j.plipres.2019.101006_bb0485","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s10695-017-0421-9","article-title":"Resveratrol supplementation improves lipid and glucose metabolism in high-fat diet-fed blunt snout bream","volume":"44","author":"Zhang","year":"2018","journal-title":"Fish Physiol Biochem"},{"key":"10.1016\/j.plipres.2019.101006_bb0490","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12986-017-0217-z","article-title":"Effects of resveratrol on glucose control and insulin sensitivity in subjects with type 2 diabetes: systematic review and meta-analysis","volume":"14","author":"Zhu","year":"2017","journal-title":"Nutr Metab"},{"issue":"2","key":"10.1016\/j.plipres.2019.101006_bb0495","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s11154-019-09494-z","article-title":"Effect of resveratrol on metabolic syndrome components: a systematic review and meta-analysis","volume":"20","author":"Asgary","year":"2019","journal-title":"Rev Endocr Metab Disord"},{"key":"10.1016\/j.plipres.2019.101006_bb0500","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.phrs.2017.12.033","article-title":"Effect of resveratrol on lipid profile: an updated systematic review and meta-analysis on randomized clinical trials","volume":"129","author":"Haghighatdoost","year":"2018","journal-title":"Pharmacol Res"},{"issue":"12","key":"10.1016\/j.plipres.2019.101006_bb0505","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1111\/nure.12081","article-title":"Effects of resveratrol supplementation on plasma lipids: a systematic review and meta-analysis of randomized controlled trials","volume":"71","author":"Sahebkar","year":"2013","journal-title":"Nutr Rev"},{"issue":"8","key":"10.1016\/j.plipres.2019.101006_bb0510","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0161792","article-title":"Efficacy of resveratrol supplementation against non-alcoholic fatty liver disease: a meta-analysis of placebo-controlled clinical trials","volume":"11","author":"Zhang","year":"2016","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.plipres.2019.101006_bb0515","doi-asserted-by":"crossref","first-page":"78","DOI":"10.15407\/ubj88.03.078","article-title":"The impact of hydroxycitric acid on the lipid metabolism profile under experimental insulin resistance syndrome of Syrian hamsters","volume":"88","author":"Zagayko","year":"2016","journal-title":"Ukrainian Biochem J"},{"issue":"1\u20132","key":"10.1016\/j.plipres.2019.101006_bb0520","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1023\/B:MCBI.0000026069.53960.75","volume":"260","author":"Shara","year":"2004","journal-title":"Mol Cell Biochem"},{"key":"10.1016\/j.plipres.2019.101006_bb0525","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12944-016-0208-5","article-title":"(-)-Hydroxycitric acid reduced fat deposition via regulating lipid metabolism-related gene expression in broiler chickens","volume":"15","author":"Han","year":"2016","journal-title":"Lipids Health Dis"},{"issue":"1","key":"10.1016\/j.plipres.2019.101006_bb0530","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/asj.12887","article-title":"Effects of (\u2212)-hydroxycitric acid on lipid droplet accumulation in chicken embryos","volume":"89","author":"Peng","year":"2018","journal-title":"Anim Sci J"},{"issue":"6","key":"10.1016\/j.plipres.2019.101006_bb0535","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1002\/ptr.5076","article-title":"Hypolipemic effect of Garcinia cambogia in obese women","volume":"28","author":"Vasques","year":"2014","journal-title":"Phytother Res"},{"issue":"3","key":"10.1016\/j.plipres.2019.101006_bb0540","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1462-8902.2004.00328.x","article-title":"Effects of a natural extract of (\u2212)-hydroxycitric acid (HCA-SX) and a combination of HCA-SX plus niacin-bound chromium and Gymnema sylvestre extract on weight loss","volume":"6","author":"Preuss","year":"2004","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.plipres.2019.101006_bb0545","doi-asserted-by":"crossref","first-page":"1583098","DOI":"10.1155\/2017\/1583098","article-title":"Cinnamon polyphenol extract inhibits Hyperlipidemia and inflammation by modulation of transcription factors in high-fat diet-fed rats","volume":"2017","author":"Tuzcu","year":"2017","journal-title":"Oxid Med Cell Longev"},{"issue":"6","key":"10.1016\/j.plipres.2019.101006_bb0550","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/j.jacl.2017.08.004","article-title":"The effects of cinnamon supplementation on blood lipid concentrations: a systematic review and meta-analysis","volume":"11","author":"Maierean","year":"2017","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.plipres.2019.101006_bb0555","series-title":"Dehydrocurvularin is a potent antineoplastic agent irreversibly blocking ATP-citrate lyase: Evidence from chemoproteomics, chemical communications (Cambridge, England)","author":"Deng","year":"2019"},{"issue":"44","key":"10.1016\/j.plipres.2019.101006_bb0560","doi-asserted-by":"crossref","first-page":"9665","DOI":"10.1021\/acs.jafc.7b03782","article-title":"Orally administered Baker\u2019s yeast beta-Glucan promotes glucose and lipid homeostasis in the livers of obesity and diabetes model mice","volume":"65","author":"Cao","year":"2017","journal-title":"J Agric Food Chem"},{"issue":"1","key":"10.1016\/j.plipres.2019.101006_bb0565","doi-asserted-by":"crossref","first-page":"23","DOI":"10.14797\/mdcj-15-1-23","article-title":"Statins: then and now","volume":"15","author":"Toth","year":"2019","journal-title":"Methodist Debakey Cardiovasc J"},{"issue":"7","key":"10.1016\/j.plipres.2019.101006_bb0570","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1080\/14656566.2019.1583209","article-title":"ETC-1002 (Bempedoic acid) for the management of hyperlipidemia: from preclinical studies to phase 3 trials","volume":"20","author":"Ruscica","year":"2019","journal-title":"Expert Opin Pharmacother"},{"issue":"8","key":"10.1016\/j.plipres.2019.101006_bb0575","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1194\/jlr.M035212","article-title":"ETC-1002 regulates immune response, leukocyte homing, and adipose tissue inflammation via LKB1-dependent activation of macrophage AMPK","volume":"54","author":"Filippov","year":"2013","journal-title":"J Lipid Res"},{"key":"10.1016\/j.plipres.2019.101006_bb0580","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.canlet.2018.02.012","article-title":"Pharmacogenomics signature: a novel strategy on the individual differences in drug response","volume":"420","author":"Guo","year":"2018","journal-title":"Cancer Lett"},{"issue":"10","key":"10.1016\/j.plipres.2019.101006_bb0585","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/nrcardio.2011.111","article-title":"The pharmacogenetics of antiplatelet agents: towards personalized therapy?","volume":"8","author":"Ahmad","year":"2011","journal-title":"Nat Rev Cardiol"},{"issue":"5","key":"10.1016\/j.plipres.2019.101006_bb0590","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1056\/NEJMc1013331","article-title":"CYP2C19 genotype and outcomes of clopidogrel treatment","volume":"364","author":"Geisler","year":"2011","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.plipres.2019.101006_bb0595","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1161\/CIRCGENETICS.108.818062","article-title":"Comprehensive whole-genome and candidate gene analysis for response to statin therapy in the Treating to New Targets (TNT) cohort","volume":"2","author":"Thompson","year":"2009","journal-title":"Circ Cardiovasc Genet"},{"issue":"11","key":"10.1016\/j.plipres.2019.101006_bb0600","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.molmed.2017.09.001","article-title":"Targeting ATP-citrate lyase in hyperlipidemia and metabolic disorders","volume":"23","author":"Pinkosky","year":"2017","journal-title":"Trends Mol Med"},{"issue":"4","key":"10.1016\/j.plipres.2019.101006_bb0605","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1093\/cvr\/cvx253","article-title":"Endothelial-mesenchymal transition in atherosclerosis","volume":"114","author":"Souilhol","year":"2018","journal-title":"Cardiovasc Res"},{"issue":"4","key":"10.1016\/j.plipres.2019.101006_bb0610","doi-asserted-by":"crossref","DOI":"10.1016\/j.molcel.2018.01.010","article-title":"A metabolic basis for endothelial-to-mesenchymal transition","volume":"69","author":"Xiong","year":"2018","journal-title":"Mol Cell"},{"issue":"1","key":"10.1016\/j.plipres.2019.101006_bb0615","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/0003-9861(69)90532-3","article-title":"Tricarballylate and hydroxycitrate: substrate and inhibitor of ATP: citrate oxaloacetate lyase","volume":"135","author":"Watson","year":"1969","journal-title":"Arch Biochem Biophys"},{"issue":"1","key":"10.1016\/j.plipres.2019.101006_bb0620","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1021\/jf010753k","article-title":"Chemistry and biochemistry of (\u2212)-hydroxycitric acid from Garcinia","volume":"50","author":"Jena","year":"2002","journal-title":"J Agric Food Chem"},{"issue":"9","key":"10.1016\/j.plipres.2019.101006_bb0625","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/j.fct.2004.04.014","article-title":"Safety assessment of (\u2212)-hydroxycitric acid and super CitriMax, a novel calcium\/potassium salt","volume":"42","author":"Soni","year":"2004","journal-title":"Food Chem Toxicol"},{"issue":"1","key":"10.1016\/j.plipres.2019.101006_bb0630","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1007\/s10637-010-9552-x","article-title":"Adding a combination of hydroxycitrate and lipoic acid (METABLOC) to chemotherapy improves effectiveness against tumor development: experimental results and case report","volume":"30","author":"Guais","year":"2012","journal-title":"Invest New Drugs"},{"issue":"1","key":"10.1016\/j.plipres.2019.101006_bb0635","first-page":"98","article-title":"Inhibition of enzymes which interact with citrate by (\u2212-)hydroxycitrate and 1,2,3,-tricarboxybenzene","volume":"38","author":"Cheema-Dhadli","year":"2010","journal-title":"FEBS J"},{"issue":"1","key":"10.1016\/j.plipres.2019.101006_bb0640","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/0005-2760(80)90194-0","article-title":"Properties and organ distribution of ATP citrate (pro-3S)-lyase","volume":"620","author":"Hoffmann","year":"1980","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"10.1016\/j.plipres.2019.101006_bb0645","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1042\/bj2720181","article-title":"The effect of (\u2212)-hydroxycitrate on the activity of the low-density-lipoprotein receptor and 3-hydroxy-3-methylglutaryl-CoA reductase levels in the human hepatoma cell line hep G2","volume":"272","author":"Berkhout","year":"1990","journal-title":"Biochem J"},{"issue":"1","key":"10.1016\/j.plipres.2019.101006_bb0650","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF02532964","article-title":"Hypolipidemic activity of (\u2212)-hydroxycitrate","volume":"12","author":"Sullivan","year":"1977","journal-title":"Lipids"},{"issue":"5","key":"10.1016\/j.plipres.2019.101006_bb0655","first-page":"1407","article-title":"A combination of alpha lipoic acid and calcium hydroxycitrate is efficient against mouse cancer models: preliminary results","volume":"23","author":"Laurent","year":"2010","journal-title":"Oncol Rep"},{"issue":"9","key":"10.1016\/j.plipres.2019.101006_bb0660","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1021\/jm00129a010","article-title":"Synthesis and hypolipidemic and antidiabetogenic activities of beta,beta,beta\u2019,beta\u2019-tetrasubstituted, long-chain dioic acids","volume":"32","author":"Bar-Tana","year":"1989","journal-title":"J Med Chem"},{"issue":"14","key":"10.1016\/j.plipres.2019.101006_bb0665","doi-asserted-by":"crossref","first-page":"8404","DOI":"10.1016\/S0021-9258(17)39488-7","article-title":"Inhibition of lipid synthesis by beta beta\u2019-tetramethyl-substituted, C14-C22, alpha, omega-dicarboxylic acids in the rat in vivo","volume":"260","author":"Bar-Tana","year":"1985","journal-title":"J Biol Chem"},{"issue":"14","key":"10.1016\/j.plipres.2019.101006_bb0670","doi-asserted-by":"crossref","first-page":"8411","DOI":"10.1016\/S0021-9258(17)39489-9","article-title":"Inhibition of lipid synthesis by beta beta\u2019-tetramethyl-substituted, C14-C22, alpha, omega-dicarboxylic acids in cultured rat hepatocytes","volume":"260","author":"Rose-Kahn","year":"1985","journal-title":"J Biol Chem"},{"issue":"5","key":"10.1016\/j.plipres.2019.101006_bb0675","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.2337\/diabetes.51.5.1548","article-title":"MEDICA 16 inhibits hepatic acetyl-CoA carboxylase and reduces plasma triacylglycerol levels in insulin-resistant JCR: LA-cp rats","volume":"51","author":"Atkinson","year":"2002","journal-title":"Diabetes"},{"issue":"2","key":"10.1016\/j.plipres.2019.101006_bb0680","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/0005-2760(90)90018-S","article-title":"Inhibition of rat liver acetyl-CoA carboxylase by beta, beta'-tetramethyl-substituted hexadecanedioic acid (MEDICA 16)","volume":"1042","author":"Rosekahn","year":"1990","journal-title":"Biochim Biophys Acta"},{"issue":"12","key":"10.1016\/j.plipres.2019.101006_bb0685","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.2337\/diab.46.12.1958","article-title":"Sensitization to insulin induced by beta,beta'-methyl-substituted hexadecanedioic acid (MEDICA 16) in obese Zucker rats in vivo","volume":"46","author":"Mayorek","year":"1997","journal-title":"Diabetes"},{"issue":"3","key":"10.1016\/j.plipres.2019.101006_bb0690","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/0005-2760(89)90083-0","article-title":"Alkylthioacetic acid (3-thia fatty acids)--a new group of non-beta-oxidizable, peroxisome-inducing fatty acid analogues. I. A study on the structural requirements for proliferation of peroxisomes and mitochondria in rat liver","volume":"1004","author":"Berge","year":"1989","journal-title":"Biochim Biophys Acta"},{"issue":"11","key":"10.1016\/j.plipres.2019.101006_bb0695","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1161\/01.ATV.13.11.1580","article-title":"Effect of 3-thiadicarboxylic acid on lipid metabolism in experimental nephrosis","volume":"13","author":"Al-Shurbaji","year":"1993","journal-title":"Arterioscl Thrombosis"},{"issue":"10","key":"10.1016\/j.plipres.2019.101006_bb0700","doi-asserted-by":"crossref","first-page":"7011","DOI":"10.1074\/jbc.M114.551051","article-title":"Glucose-dependent de novo lipogenesis in B lymphocytes: a requirement for atp-citrate lyase in lipopolysaccharide-induced differentiation","volume":"289","author":"Dufort","year":"2014","journal-title":"J Biol Chem"}],"container-title":["Progress in Lipid Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163782719300499?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163782719300499?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T22:41:03Z","timestamp":1759012863000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163782719300499"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":140,"alternative-id":["S0163782719300499"],"URL":"https:\/\/doi.org\/10.1016\/j.plipres.2019.101006","relation":{},"ISSN":["0163-7827"],"issn-type":[{"value":"0163-7827","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ATP-citrate lyase (ACLY) in lipid metabolism and atherosclerosis: An updated review","name":"articletitle","label":"Article Title"},{"value":"Progress in Lipid Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.plipres.2019.101006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101006"}}